Drug intelligence / Profile preview

IL23R

Development stage: Preclinical
Lead developer: AbbVie
Modality: Peptides
Administration: Oral

Overview

IL23R is an investigational oral peptide inhibitor targeting the Interleukin-23 receptor (IL23R). Originally developed by Nimble Therapeutics, it was acquired by AbbVie on January 23, 2025. This drug is currently in preclinical development for the treatment of psoriasis and inflammatory bowel disease, aiming to strengthen AbbVie's immunology pipeline with novel oral peptide therapeutics.

Other names: investigational oral peptide IL23R inhibitor

Targets

IL23R (Interleukin-23 Receptor)

Beyond the preview

Go deeper on IL23R.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IL23R.

Explore the full profile